StockData
Sarepta Therapeutics, Inc. logo

Sarepta Therapeutics, Inc. (SRPT) stock

SRPTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 12/3086% below fair value
$14.53−0.24 (-1.62%)

Close on Nov 18, 2026Market cap $1.53BP/E –Yield –

Sarepta Therapeutics free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Sarepta Therapeutics's free cash flow for the twelve months ending Jun 30, 2026 was $81.85M. For fiscal 2025 it was -$307.45M. The highest annual figure on record is $25.26M in fiscal 2020.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$307.45M–
FY2024Dec 31, 2024-$342.74M–
FY2023Dec 31, 2023-$577.10M–
FY2022Dec 31, 2022-$356.17M–
FY2021Dec 31, 2021-$481.66M-2006.5%
FY2020Dec 31, 2020$25.26M–
FY2019Dec 31, 2019-$516.09M–
FY2018Dec 31, 2018-$449.82M–
FY2017Dec 31, 2017-$244.00M–
FY2016Dec 31, 2016-$251.16M–
FY2015Dec 31, 2015-$152.87M–
FY2014Dec 31, 2014-$153.98M–
FY2013Dec 31, 2013-$67.07M–
FY2012Dec 31, 2012-$29.80M–
FY2011Dec 31, 2011-$24.86M–
FY2010Dec 31, 2010-$16.04M–
FY2009Dec 31, 2009-$9.73M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$196.52M-14.4%
Q1 FY2026Mar 31, 2026-$204.76M–
Q4 FY2025Dec 31, 2025$127.62M+136.5%
Q3 FY2025Sep 30, 2025-$37.52M–
Q2 FY2025Jun 30, 2025$229.54M–
Q1 FY2025Mar 31, 2025-$627.09M–
Q4 FY2024Dec 31, 2024$53.96M–
Q3 FY2024Sep 30, 2024-$107.96M–
Q2 FY2024Jun 30, 2024-$14.23M–
Q1 FY2024Mar 31, 2024-$274.52M–
Q4 FY2023Dec 31, 2023-$73.70M–
Q3 FY2023Sep 30, 2023-$144.38M–
Q2 FY2023Jun 30, 2023-$140.14M–
Q1 FY2023Mar 31, 2023-$218.88M–
Q4 FY2022Dec 31, 2022-$100.36M–
Q3 FY2022Sep 30, 2022-$73.20M–
Q2 FY2022Jun 30, 2022-$75.89M–
Q1 FY2022Mar 31, 2022-$106.73M–
Q4 FY2021Dec 31, 2021-$31.53M–
Q3 FY2021Sep 30, 2021-$133.57M–
Q2 FY2021Jun 30, 2021-$115.04M–
Q1 FY2021Mar 31, 2021-$201.52M-132.6%
Q4 FY2020Dec 31, 2020-$203.15M–
Q3 FY2020Sep 30, 2020-$263.49M–
Q2 FY2020Jun 30, 2020-$126.77M–
Q1 FY2020Mar 31, 2020$618.67M–
Q4 FY2019Dec 31, 2019-$181.05M–
Q3 FY2019Sep 30, 2019-$76.86M–
Q2 FY2019Jun 30, 2019-$95.69M–
Q1 FY2019Mar 31, 2019-$162.50M–
Q4 FY2018Dec 31, 2018-$142.62M–
Q3 FY2018Sep 30, 2018-$133.41M–
Q2 FY2018Jun 30, 2018-$125.95M–
Q1 FY2018Mar 31, 2018-$47.83M–
Q4 FY2017Dec 31, 2017-$34.96M–
Q3 FY2017Sep 30, 2017-$58.67M–
Q2 FY2017Jun 30, 2017-$88.02M–
Q1 FY2017Mar 31, 2017-$62.35M–
Q4 FY2016Dec 31, 2016-$84.15M–
Q3 FY2016Sep 30, 2016-$61.46M–

More Sarepta Therapeutics figures

See a number that looks wrong?